EUVIMEDEUVIMED entdecken
Open Access

Real‐World Experience With a ZUMA ‐1 Cohort 4 Adopted Approach to CRS and ICANS in CAR ‐T Recipients

Chiranjeevi Sainatham, Olga Goloubeva, Philip Margiotta, Hanan Alharthy, Imari Patel, Greeshma Gaddipati, Ali Bukhari iD, Jennie Law, Seung Tae Lee, Mehmet Kocoglu iD, Jean Yared, Nancy Hardy und 7 weitere

European Journal of Haematology · 2026

DOI: 10.1111/ejh.70216 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, 2026. Verfasst von Chiranjeevi Sainatham und 18 weiteren Autor:innen. Beteiligte Einrichtung: University of Florida, Gainesville, Florida, USA. Hauptthemen laut MEDLINE: Cytokine Release Syndrome, Immunotherapy, Adoptive, Neurotoxicity Syndromes, Receptors, Chimeric Antigen. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Axicabtagene ciloleucel (Axi‐cel) is a chimeric antigen receptor T‐cell (CAR‐T) therapy approved for the treatment of relapsed/refractory (R/R) large B‐cell lymphoma (LBCL). The registrational phase 1/2 ZUMA‐1 study cohorts 1 and 4 addressed toxicity management in terms of cytokine release syndrome (CRS) and immune effector cell‐associated neurotoxicity syndrome (ICANS) whereby tocilizumab and corticosteroids were deployed earlier in cohort 4. In this real‐world, single‐institution study of 119 patients receiving Axi‐cel CAR‐T therapy for R/R LBCL with 70 in cohort 1 and 49 in cohort 4, we demonstrate significantly less toxicity, intensive care unit (ICU) utilization, and cumulative steroid use with an early intervention strategy. Laboratory parameters and comorbidities did not significantly differ between groups except for a higher incidence of renal insufficiency in the cohort 4 group (28.6% vs. 4.3%, p < 0.01). The maximum grade CRS was significantly lower for cohort 4 versus 1 (1 vs. 2, p < 0.01). Furthermore, cumulative corticosteroid use was significantly less in the cohort 4 early intervention group (110 mg vs. 190 mg dexamethasone equivalents). These favorable findings did not have a deleterious impact on outcomes and efficacy with similar overall response rate, progression‐free survival, and overall survival with both toxicity management approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytokine Release SyndromeImmunotherapy, AdoptiveNeurotoxicity SyndromesReceptors, Chimeric AntigenLymphoma, Large B-Cell, DiffuseHumansFemaleMaleMiddle AgedAgedTreatment OutcomeAdultBiological Products

Substanzen

Receptors, Chimeric Antigenaxicabtagene ciloleucelBiological Products

Autor:innen und Institutionen

  • University of Florida, Gainesville, Florida, USA.
  • University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • University of Maryland Medical Center, Baltimore, Maryland, USA.
  • Medstar Union Memorial Hospital, Baltimore, Maryland, USA.
  • University of Kansas Medical Center, Kansas City, Kansas, USA.
  • Stanford Medicine, Stanford, California, USA.

ORCID-Profile: Ali Bukhari, Mehmet Kocoglu, Forat Lutfi

Zitieren

APA

Sainatham, C., Goloubeva, O., Margiotta, P., Alharthy, H., Patel, I., Gaddipati, G., Bukhari, A., Law, J., Lee, S. T., Kocoglu, M., Yared, J., Hardy, N., Nelson, M., Ahmed, N., Mushtaq, M. U., McGuirk, J., Rapoport, A. P., Dahiya, S., & Lutfi, F. (2026). Real‐World Experience With a ZUMA ‐1 Cohort 4 Adopted Approach to CRS and ICANS in CAR ‐T Recipients. European Journal of Haematology. https://doi.org/10.1111/ejh.70216

Vancouver

Sainatham C, Goloubeva O, Margiotta P, Alharthy H, Patel I, Gaddipati G, et al. Real‐World Experience With a ZUMA ‐1 Cohort 4 Adopted Approach to CRS and ICANS in CAR ‐T Recipients. European Journal of Haematology. 2026. doi:10.1111/ejh.70216

BibTeX
@article{Sainatham2026,
  author = {Sainatham, Chiranjeevi and Goloubeva, Olga and Margiotta, Philip and Alharthy, Hanan and Patel, Imari and Gaddipati, Greeshma and Bukhari, Ali and Law, Jennie and Lee, Seung Tae and Kocoglu, Mehmet and Yared, Jean and Hardy, Nancy and Nelson, Maggie and Ahmed, Nausheen and Mushtaq, Muhammad Umair and McGuirk, Joseph and Rapoport, Aaron P and Dahiya, Saurabh and Lutfi, Forat},
  title = {Real‐World Experience With a ZUMA ‐1 Cohort 4 Adopted Approach to CRS and ICANS in CAR ‐T Recipients},
  journal = {European Journal of Haematology},
  year = {2026},
  doi = {10.1111/ejh.70216}
}
Kostenlos starten →